Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00408629
Registration number
NCT00408629
Ethics application status
Date submitted
5/12/2006
Date registered
7/12/2006
Date last updated
3/05/2011
Titles & IDs
Public title
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
Query!
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Query!
Secondary ID [1]
0
0
2006-002782-40
Query!
Secondary ID [2]
0
0
M06-827
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - adalimumab
Other interventions - placebo
Experimental: adalimumab group -
Experimental: placebo group -
Other interventions: adalimumab
Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
Other interventions: placebo
Matching Placebo for prefilled syringe, 40 mg,
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8
Query!
Assessment method [1]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), Endoscopy Subscore, and Physician's Global Assessment Subscore (PGA), each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [1]
0
0
Week 8
Query!
Primary outcome [2]
0
0
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52
Query!
Assessment method [2]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [1]
0
0
Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52
Query!
Assessment method [1]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [1]
0
0
Week 8, Week 52
Query!
Secondary outcome [2]
0
0
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8
Query!
Assessment method [2]
0
0
Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in rectal bleeding subscore (RBS) of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [2]
0
0
Week 8
Query!
Secondary outcome [3]
0
0
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52
Query!
Assessment method [3]
0
0
Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [3]
0
0
Week 52
Query!
Secondary outcome [4]
0
0
Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52
Query!
Assessment method [4]
0
0
Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [4]
0
0
Week 8, Week 52
Query!
Secondary outcome [5]
0
0
Proportion of Participants Who Achieved Mucosal Healing at Week 8
Query!
Assessment method [5]
0
0
Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:
0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).
Query!
Timepoint [5]
0
0
Week 8
Query!
Secondary outcome [6]
0
0
Proportion of Participants Who Achieved Mucosal Healing at Week 52
Query!
Assessment method [6]
0
0
Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:
0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).
Query!
Timepoint [6]
0
0
Week 52
Query!
Secondary outcome [7]
0
0
Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52
Query!
Assessment method [7]
0
0
Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:
0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).
Query!
Timepoint [7]
0
0
Week 8, Week 52
Query!
Secondary outcome [8]
0
0
Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52
Query!
Assessment method [8]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [8]
0
0
Baseline to Week 52
Query!
Secondary outcome [9]
0
0
Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Query!
Assessment method [9]
0
0
The PGA includes the 3 other subscores (SFS, RBS, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from 0-3 as follows:
0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).
Query!
Timepoint [9]
0
0
Week 8
Query!
Secondary outcome [10]
0
0
Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Query!
Assessment method [10]
0
0
SFS ranges from 0-3 as follows:
0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. The participant served as his/her own control.
Query!
Timepoint [10]
0
0
Week 8
Query!
Secondary outcome [11]
0
0
Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Query!
Assessment method [11]
0
0
RBS ranges from 0-3 as follows:
0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed
Query!
Timepoint [11]
0
0
Week 8
Query!
Secondary outcome [12]
0
0
Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52
Query!
Assessment method [12]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [12]
0
0
Baseline to Week 52
Query!
Secondary outcome [13]
0
0
Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52
Query!
Assessment method [13]
0
0
Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:
SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).
Query!
Timepoint [13]
0
0
Week 32, Week 52
Query!
Secondary outcome [14]
0
0
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52
Query!
Assessment method [14]
0
0
Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
Query!
Timepoint [14]
0
0
Week 52
Query!
Secondary outcome [15]
0
0
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8
Query!
Assessment method [15]
0
0
Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
Query!
Timepoint [15]
0
0
Week 8
Query!
Eligibility
Key inclusion criteria
1. Participants >=18 years of age and in good health (Investigator discretion) with a
recent stable medical history
2. Diagnosis of UC for greater than 90 days prior to Baseline
3. Diagnosis of active UC confirmed by colonoscopy with biopsy or flexible sigmoidoscopy
with biopsy during the Screening Period, with exclusion of infection
4. Active UC with a Mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 points,
despite concurrent treatment with at least 1 of the following (oral corticosteroids or
immunosuppressants or both as defined below):
- Stable oral corticosteroid dose (prednisone >= 20 mg/day or equivalent) for at
least 14 days prior to Baseline or maintenance, corticosteroid dose (prednisone <
20 mg/day or equivalent) for at least 40 days prior to Baseline
and/or
- At least a 90 day course of azathioprine (AZA) or 6-mercaptopurine (6-MP) prior
to Baseline, with a dose of AZA >= 1.5 mg/kg/day or 6-MP >= 1 mg/kg/day (rounded
to the nearest available tablet formulation), or a dose that is the highest
tolerated by the participant (e.g., due to leukopenia, elevated liver enzymes,
nausea) during that time. Participant must be on a stable dose for at least 28
days prior to Baseline.
Concurrent therapy was not required for participants who were previously treated with
corticosteroids or immunosuppressants (AZA or 6-MP) during the past 5 years and in the
judgment of the Investigator have failed to respond to, or could not tolerate, their
treatment.
5. Participants may have been included if they had previously used an anti-tumor necrosis
factor (TNF) agent (except ADA) and discontinued its use due to a loss of response or
intolerance to the agent.
6. Had to be able to self-administer or had caregiver who could reliably administer
subcutaneous (SC) injections.
7. Had to be able and willing to give written informed consent and to comply with the
requirements of the study protocol.
8. Female had to be either not of childbearing potential, defined as postmenopausal for
at least 1 year or surgically sterile (bilateral tubal ligation, bilateral
oophorectomy, or hysterectomy), or of childbearing potential and practicing an
approved method of birth control throughout the study and for 150 days after the last
dose of study drug. Examples of approved methods of birth control included the
following:
- Condoms, sponge, foams, jellies, diaphragm, or intrauterine device
- Oral, parenteral, intravaginal contraceptives for 90 days prior to study drug
administration
- A vasectomized partner The results of the serum pregnancy test performed at the
Screening Visit and urine pregnancy test performed at the Baseline Visit must
have been negative.
9. Judged to be in generally good health as determined by the Investigator
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch,
Koch pouch, or ileostomy for UC, or planned bowel surgery.
2. Received previous treatment with ADA or previous participation in an ADA clinical
study.
3. Received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days of
Baseline.
4. Received intravenous (IV) corticosteroids within 14 days of Screening or during the
Screening Period.
5. Received therapeutic enema or suppository, other than required for endoscopy, within
14 days of the Screening endoscopy and during the remainder of the Screening Period.
6. Current diagnosis of fulminant colitis and/or toxic megacolon.
7. Disease limited to the rectum (ulcerative proctitis).
8. Current diagnosis of indeterminate colitis.
9. Current diagnosis and/or history of Crohns disease (CD).
10. Currently receiving total parenteral nutrition.
11. Used aminosalicylates for < 90 days before Baseline or not on a stable dose for at
least 28 days before Baseline or discontinued use within 28 days of Baseline.
12. Positive Clostridium difficile stool assay.
13. Previously used infliximab or any anti-TNF agent within 56 days of Baseline.
14. Previously used infliximab or any anti-TNF agent without clinical response at any time
("primary non-responder") unless subject experienced a treatment-limiting reaction.
15. Infections requiring treatment with IV antibiotics, antivirals, or antifungals within
30 days of Baseline or oral antibiotics, antivirals, or antifungals within 14 days of
Baseline.
16. History of malignancy other than a successfully treated non-metastatic cutaneous
squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the
cervix. If the Screening colonoscopy/flexible sigmoidoscopy showed evidence of
dysplasia or a malignancy, subject was not to be enrolled in the study.
17. History of listeria, histoplasmosis, chronic or active hepatitis B infection, human
immunodeficiency virus (HIV), immunodeficiency syndrome, central nervous system
demyelinating disease, or untreated tuberculosis (TB).
18. Female subject who was pregnant or breast-feeding or considering becoming pregnant
during the study (there should be at least 150 days between the last dose of study
drug and either conception or initiation of breast-feeding in women of childbearing
potential).
19. Poorly controlled medical condition(s), such as uncontrolled diabetes, unstable
ischemic heart disease, moderate to severe congestive heart failure (CHF), recent
cerebrovascular accident, and any other condition, which in the opinion of the
investigator, put the subject at risk by participation in the protocol.
20. Received any investigational agent within 30 days or 5 half lives prior to Baseline
(whichever was longer).
21. History of clinically significant drug or alcohol abuse during the past year.
22. Known hypersensitivity to the excipients of ADA as stated in the label.
23. Any prior exposure to Tysabri® (natalizumab), or Orencia® (abatacept) or any other
biological therapy [other than Kineret® (anakinra) and anti-TNF agents].
24. Currently taking both budesonide and prednisone (or equivalent) simultaneously.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
518
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Site Ref # / Investigator 13722 - Garran
Query!
Recruitment hospital [2]
0
0
Site Ref # / Investigator 16141 - Bankstown
Query!
Recruitment hospital [3]
0
0
Site Ref # / Investigator 13723 - Herston
Query!
Recruitment hospital [4]
0
0
Site Ref # / Investigator 10706 - Bedford Park
Query!
Recruitment hospital [5]
0
0
Site Ref # / Investigator 14882 - Box Hill
Query!
Recruitment hospital [6]
0
0
Site Ref # / Investigator 9002 - Malvern
Query!
Recruitment hospital [7]
0
0
Site Ref # / Investigator 10704 - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
NSW 2200 - Bankstown
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
SA 5042 - Bedford Park
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [7]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oklahoma
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Vienna
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Bonheiden
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Brussels
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Ghent
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Leuven
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Ceske Budejovice
Query!
Country [32]
0
0
Czech Republic
Query!
State/province [32]
0
0
Hradec Kravlove 12
Query!
Country [33]
0
0
Czech Republic
Query!
State/province [33]
0
0
Olomouc
Query!
Country [34]
0
0
Czech Republic
Query!
State/province [34]
0
0
Prague 4
Query!
Country [35]
0
0
Czech Republic
Query!
State/province [35]
0
0
Prague 5
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Hvidovre
Query!
Country [37]
0
0
Denmark
Query!
State/province [37]
0
0
Odense C
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Clichy
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Lille Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Pessac Cedex
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Toulouse
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Hamburg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Magdeburg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Minden
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Muenster
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Munich
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Regensburg
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Budapest
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Debrecen
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Gyula
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Miskoic
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Miskolc
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Kfar Saba
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Petah Tikva
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Tel Aviv
Query!
Country [56]
0
0
New Zealand
Query!
State/province [56]
0
0
Auckland
Query!
Country [57]
0
0
New Zealand
Query!
State/province [57]
0
0
Christchurch
Query!
Country [58]
0
0
New Zealand
Query!
State/province [58]
0
0
Hamilton
Query!
Country [59]
0
0
Norway
Query!
State/province [59]
0
0
Gjovik
Query!
Country [60]
0
0
Norway
Query!
State/province [60]
0
0
Oslo
Query!
Country [61]
0
0
Norway
Query!
State/province [61]
0
0
Tromso
Query!
Country [62]
0
0
Norway
Query!
State/province [62]
0
0
Trondheim
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lodz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Warsaw
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Wroclaw
Query!
Country [66]
0
0
Portugal
Query!
State/province [66]
0
0
Faro
Query!
Country [67]
0
0
Portugal
Query!
State/province [67]
0
0
Lisbon
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Barcelona
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Madrid
Query!
Country [70]
0
0
Switzerland
Query!
State/province [70]
0
0
Basel
Query!
Country [71]
0
0
Switzerland
Query!
State/province [71]
0
0
Bern
Query!
Country [72]
0
0
Switzerland
Query!
State/province [72]
0
0
Zurich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Abbott
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed
to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal
antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis
(UC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00408629
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Roopal B Thakkar, M.D.
Query!
Address
0
0
Abbott
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00408629
Download to PDF